

# Mitavipat

## Adjudication Guideline

**Rule Category:**  
Medical

**Ref: No:**  
2023-PH-0031

**Version Control:**  
Version No.1.0

**Effective Date:**  
30/09/2023

**Revision Date:**  
30/09/2023

**Approved by:**  
Daman

**Responsible:**  
Medical Standards  
& Research

**Related Adjudication  
Guidelines:**

## Table of Contents

1.	Abstract .....	3
1.1	For Members.....	3
1.2	For Medical Professionals.....	3
2.	Scope .....	3
3.	Adjudication Policy.....	4
3.1	Eligibility / Coverage Criteria.....	4
3.2	Requirements for Coverage .....	4
3.3	Non-Coverage.....	4
3.4	Payment and Coding Rules .....	4
4.	Denial codes .....	4
5.	Appendices .....	5
5.1	References .....	5
5.2	Revision History .....	5

## 1. Abstract

### 1.1 For Members

Mitavipat is indicated for the treatment of haemolytic anemia in adults with pyruvate kinase (PK) deficiency, an inherited disease that causes red blood cells to break down faster than normal.

### 1.2 For Medical Professionals

Mitavipat will be reviewed by High-cost team, relevant reports pertaining to treatment history, frequency, and dosage for the indications should be delivered upon request for further review.

Relevant clinicians are only permitted to order the medication.

Current Dose	DOSE TAPER SCHEDULE		
	Day 1-7	Day 8-14	Day 15
5 mg twice daily	5 mg once daily	Discontinue	N/A
20 mg twice daily	20 mg once daily	5 mg once daily	Discontinue
50 mg twice daily	50 mg once daily	20 mg once daily	Discontinue

#### Dose Titration Schedule:

Duration	Check	Dosage
Week 1 through Week 4	N/A	5mg twice daily.
Week 5 through Week 8	If Hb is below normal range or patient has required a transfusion within the last 8 weeks.	Increase to 20 mg twice daily and maintain for 4 weeks.
	If Hb is within normal range and patient has not required a transfusion within the last 8 weeks.	Maintain 5 mg twice daily.
Week 9 through Week 12	If Hb is below normal range or patient has required a transfusion within the last 8 weeks	Increase to 50 mg twice daily and maintain thereafter.
	If Hb is within normal range and patient has not required a transfusion within the last 8 weeks	Maintain current dose (5 mg twice daily or 20 mg twice daily).
Maintenance	If Hb decreases.	consider up-titration to the maximum of 50 mg twice daily as per the above schedule.

## 2. Scope

This Adjudication Rule highlights the coverage and payment requirements by Daman as per policy terms and conditions for Mitavipat. It also highlights the medical criteria for coverage.

## 3. Adjudication Policy

### 3.1 Eligibility / Coverage Criteria

- Mitavipat is indicated for the treatment of haemolytic anemia in adults with pyruvate kinase (PK) deficiency, an inherited disease that causes red blood cells to break down faster than normal.
- 1. The safety and efficacy of Mitavipat in Pediatric patients has not been established.
- 2. The eligible ordering clinicians are haematologists, Internal medicine.
- 3. It has plan-wise coverage and can be billed based on medical necessity.
- 4. Mitapivat dosage frequency is twice daily regardless of the dose 5mg, 20mg or 50mg as it requires monthly evaluation. Reports with levels of Hb, transfusion details if required should be documented.

### 3.2 Requirements for Coverage

All the relevant documents should be submitted upon request, also providing the history of treatment, the frequency or dosage related to the same.

### 3.3 Non-Coverage

Covered by all plans except visitor's plan.

### 3.4 Payment and Coding Rules

Please apply regulator payment rules and regulations and relevant coding manuals for ICD, CPT, etc. Kindly code the ICD-10 and the CPT codes to the highest level of specificity.

**Table 1: Eligible clinicians**

Eligible Ordering Grouping
Hematologists
Internal medicine

## 4. Denial Codes

DOH denial codes with description are elaborated for reference. These are specialized codes directed by DOH, that explains the reason of rejection of the service by DAMAN to the providers.

Code	Code Description
MNEC 003	Diagnoses are not covered
MNEC 004	Service is not clinically indicated based on good clinical practice
CODE-010	Activity/diagnosis inconsistent with clinician's specialty
CLN-001	Activity/diagnosis inconsistent with clinician specialty
NCOV-003	Service(s) is (are) not covered

## 5. Appendices

### 5.1 References

<https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd>  
<https://go.drugbank.com/drugs/DB16236>  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/216196s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf)

### 5.2 Revision History

Date	Change(s)
30/08/2023	Release of V1.0

#### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by The National Insurance Company – Daman (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.